NASDAQ:DOXAmdocs Stock Price, Forecast & News

Amdocs' stock was trading at $61.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DOX shares have decreased by 3.5% and is now trading at $59.26. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amdocs in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amdocs.

Amdocs is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Amdocs.

Amdocs will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Amdocs Limited (NASDAQ:DOX) announced its quarterly earnings results on Thursday, May, 7th. The technology company reported $1.08 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.06 by $0.02. The technology company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.04 billion. Amdocs had a net margin of 11.98% and a return on equity of 16.03%. Amdocs's revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.06 earnings per share. View Amdocs' earnings history.

Amdocs announced a quarterly dividend on Thursday, May 7th. Investors of record on Tuesday, June 30th will be paid a dividend of $0.327 per share on Friday, July 24th. This represents a $1.31 dividend on an annualized basis and a yield of 2.21%. The ex-dividend date is Monday, June 29th. View Amdocs' dividend history.

Amdocs issued an update on its third quarter earnings guidance on Thursday, May, 7th. The company provided earnings per share guidance of $1.00 to $1.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.16. The company issued revenue guidance of $990 million to $1.040 billion, compared to the consensus revenue estimate of $1.05 billion.

5 Wall Street analysts have issued 1 year target prices for Amdocs' stock. Their forecasts range from $72.00 to $85.00. On average, they anticipate Amdocs' share price to reach $76.40 in the next twelve months. This suggests a possible upside of 28.9% from the stock's current price. View analysts' price targets for Amdocs.

Media stories about DOX stock have trended very negative on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amdocs earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Amdocs.

Some companies that are related to Amdocs include Accenture (ACN), IBM (IBM), Cognizant Technology Solutions (CTSH), EPAM Systems (EPAM), Leidos (LDOS), Gartner (IT), Booz Allen Hamilton (BAH), Caci International (CACI), Mantech International (MANT), Teradata (TDC), Virtusa (VRTU), Unisys (UIS), Forrester Research (FORR), The Hackett Group (HCKT) and Servicesource International (SREV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amdocs investors own include AbbVie (ABBV), Comcast (CMCSA), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Home Depot (HD), Intel (INTC), Pfizer (PFE), Verizon Communications (VZ) and Cisco Systems (CSCO).

Amdocs trades on the NASDAQ under the ticker symbol "DOX."

Amdocs' stock is owned by a number of institutional and retail investors. Top institutional investors include Wedge Capital Management L L P NC (0.63%), Envestnet Asset Management Inc. (0.10%), UNIVEST FINANCIAL Corp (0.08%), State of Alaska Department of Revenue (0.05%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%) and Groesbeck Investment Management Corp NJ (0.01%).

DOX stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., State of Alaska Department of Revenue, and Nelson Van Denburg & Campbell Wealth Management Group LLC.

DOX stock was bought by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, UNIVEST FINANCIAL Corp, Groesbeck Investment Management Corp NJ, Mount Yale Investment Advisors LLC, Private Trust Co. NA, Moody National Bank Trust Division, Diversified Trust Co, and Carroll Financial Associates Inc..

Shares of DOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DOX stock can currently be purchased for approximately $59.26.

Amdocs has a market capitalization of $7.99 billion and generates $4.09 billion in revenue each year. The technology company earns $479.45 million in net income (profit) each year or $4.07 on an earnings per share basis. Amdocs employs 24,516 workers across the globe.

The official website for Amdocs is www.amdocs.com.

Amdocs' mailing address is 1390 Timberlake Manor Parkway, Chesterfield MO, 63017. The technology company can be reached via phone at 1 314 212 7000 or via email at [email protected]